Mitomycin Injection

  • Medicine Name- Jelmyto 
  • API- Mitomycin
  • Packaging- Single-Use Vial
  • Strength-  40 mg single-dose vials
  • Manufactured by: Zydus Celexa
Get an Enquiry

Description

  • The alkylating medication Mitomycin is recommended for treating adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC).

Dosage and Side Effects

  • Usage Guidelines: Mitomycin is meant for use directly in the pyelocalyceal area. It should not be used intravenously, topically, or taken by mouth. 
  • Pre-Instillation Preparation: Take 1.3 grams of sodium bicarbonate orally the night before, in the morning, and 30 minutes before the instillation procedure. This adds up to a total of 3.9 grams.
  • Installation Dosage: The recommended dose of Mitomycin to be instilled is 4 milligrams per milliliter through a ureteral catheter or nephrostomy tube. The total instillation volume should be determined using pyelography measurements, capped at 15 milliliters (equivalent to 60 milligrams of Mitomycin).
  • Treatment Schedule: Administer Mitomycin 40 mg once a week for six weeks. If a patient shows a complete response three months after starting Mitomycin, subsequent installations may be given once a month for a maximum of 11 additional sessions.

The most frequent side effects (≥20%) include fatigue, nausea, vomiting, dysuria, ureteric blockage, flank discomfort, urinary tract infection, hematuria, and renal failure.

Warning and Precautions

  • Ureteric Obstruction: There’s a chance that this will happen. Patients should be kept an eye out for ureteric blockage symptoms and indicators. Using temporary or permanent ureteral stents or other operations may be necessary. Mitomycin should be withheld or stopped permanently, depending on how severe the ureteric blockage is. 
  •  Bone Marrow Suppression: Neutropenia and thrombocytopenia could manifest. Observe the blood counts. Depending on the severity, withhold or stop using Mitomycin completely.
  • Embryo-fetal toxicity: May be harmful to the fetus.

FAQ's

Does the FDA approve Mitomycin?

On April 15, 2020, the Food and Drug Administration approved Mitomycin (JELMYTO, UroGen Pharma) for adult patients with low-grade upper tract urothelial cancer (LG-UTUC).

Is Mitomycin used in chemotherapy?

Mitomycin is a chemotherapy drug used to treat different cancers, including breast, bladder, stomach, pancreatic, anal, and lung cancers.

Why use Mitomycin?

Mitomycin C (MMC) is an antimetabolite used during the initial stages of a trabeculectomy to prevent excessive postoperative scarring and thus reduce the risk of failure.

What are the uses of Mitomycin?

Mitomycin 40 mg solution is used to treat symptoms of pancreatic and stomach cancer and is under clinical research for its potential to treat

  • Gastrointestinal strictures
  • Wound healing from glaucoma surgery
  • Corneal excimer laser surgery
  • And endoscopic dacryocystorhinostomy.

What are the ingredients in the medicine with Mitomycin?

The medication’s active ingredient is Mitomycin, and the inactive ingredient is Mannitol.